Advair Diskus has a market value of approximately $3 billion for the 12 months ended February 2021, although actual generic market values are expected to be lower.

After the FDA shot down Mylan’s generic Advair for the second time in June, executives said they addressed the “minor deficiencies” and an approval should follow in mid-October. A week into ...

Advair Diskus had a market value of approximately $3 billion for the 12 months ending April 2021, although actual generic market values are expected to be lower.

Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in ...

Mylan has finally presented an ANDA for a generic Advair. Innoviva (formerly Theravance) sold off once again. Here is what the availability of generic Advair likely implies for INVA. Advair is one ...

A generic for Advair is still on the near-term horizon. Even if Mylan's issues are more substantial and therefore take longer to get sorted, the likelihood is that they will be sorted.

GlaxoSmithKline's Advair is hard to copy. Some companies have given up on generic Advair, while others have shied away altogether despite the substantial sales up for grabs. But what if generics ...

GlaxoSmithKline shares gained on Wednesday as lack of news about U.S. approval of a generic copy of its blockbuster inhaled lung drug Advair buoyed speculation that a threat to profits might be ...

The U.S. Food and Drug Administration (FDA) approved Mylan NV's generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday.

By Ben Hirschler LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they ...

Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline's GSK Advair Diskus - Wixela Inhub - following a few setbacks. Notably, this is the first ...

A deadline for U.S. regulators to give a verdict on a generic copy of GlaxoSmithKline's (GSK.L) blockbuster inhaled lung drug Advair has passed with no sign of approval, sparking speculation that a ...